Big Generic Drug Deal for Lannett

The month of September got off to a busy start, with more than 32 acquisitions announced in just the first week. The biggest deal, by disclosed price, was Lannett Company‘s (NYSE: LCI) $1.23 billion bid for Kremers Urban Pharmaceuticals, a subsidiary of UCB S.A. (Euronext: UCB). The deal adds near-term growth potential for LCI, with […]